InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,304.72
(
0.70%
)
US TECH 100
18,318.00
(
0.95%
)
Dow Jones
39,069.59
(
0.01%
)
Brent Oil
81.97
(
0.00%
)
Bitcoin
69,068.70
(
0.79%
)
Post# of 251939
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

ghmm

Send PM Follow Ignore
Followers 50
Posts 6343
Boards Moderated 0
Alias Born 01/22/2006

ghmm

Re: DewDiligence post# 223147

Monday, 01/14/2019 6:26:10 PM

Monday, January 14, 2019 6:26:10 PM

Post# of 251939
I was surprised to hear NKTR evaluating one of their oncology drugs in virology with Gilead. I believe they said HIV but the slide seems to allude to other possibilities. It's not a partnership per se each provides drug and maintain ownership. Gilead has the right of first refusal (for Virology only) though if NKTR decides to partner.

Slides 28 & 29 from the webcast here is a link for anyone interested

https://www.nektar.com/application/files/2315/4696/3638/JPM_2019_Nektar_Therapeutics.pdf
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up